{
    "symbol": "TBPH",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-07 04:59:06",
    "content": " Looking specifically at the Theravance field sales deployment efforts on Slide 8, in Q1 of 2022, doses sold exclusively in the hospital setting represented a year-over-year increase of 73.2% from Q1 of 2021 and an increase of 4.3% from the prior quarter demonstrating the highest quarter volume launch to date. The ampreloxetine Phase 3 program included three studies, Study 0169, Study 0170 and the open-label extension Study 0171, and enrolled patients with Parkinson\u2019s disease, multiple system atrophy or MSA and pure autonomic failure. GSK noted that TRELEGY continued to lead the market as a single inhaler triple therapy with year-over-year global sales growth of 33%, generating global net sales of $454 million during the first quarter of 2022."
}